Table 3. Characteristics of dengue... | Rockefeller University Press

Table 3.

Characteristics of dengue patients with IFN-neutralizing effects

No. and group	Sex	Age (years)	DENV serotype	NAbs	Outcomes	Symptoms	Hemorrhage-related parameters			Organ injury or abnormality
No. and group	Sex	Age (years)	DENV serotype	NAbs	Outcomes	Symptoms	PLT (×10⁹/L)	HB (g/L)	HCT (%)	Cardiac	Hepatic	Kidney	Lung
P1 (DHF)	M	53	DENV-1	IFN-α2	Survival	Thrombocytopenia, mucosal bleeding	57	145	44.2	++ Myocardial damage	++	–	–
P2 (DHF)	F	78	DENV-1	IFN-α2	Survival	Hypoalbuminemia, palpitation	93	79	24	++ Heart failure, myocarditis, and paroxysmal atrial fibrillation	–	+	–
P3 (DHF)	M	86	DENV-1	IFN-α2	Survival	Diarrhea, mucosal bleeding	77	115	34.5	+ Sinus bradycardia, aortic regurgitation, and left ventricular diastolic dysfunction	++	–	+
P4 (DHF)	M	55	Unknown	IFN-ω	Survival	Abdominal discomfort, epistaxis, and thrombocytopenia	17	128	38.5	+ Mitral regurgitation, and tricuspid regurgitation	++	–	–
P5 (DSS)	F	48	DENV-1	IFN-ω	Death	Thrombocytopenia, abdominal pain, diarrhea, and septic shock	13	40	<15	++ Myocarditis, paroxysmal atrial fibrillation	+	+	++
P6 (DHF)	F	75	DENV-1	IFN-α2/IFN-ω	Survival	Thrombocytopenia, abdominal discomfort	14	123	38.2	++ Heart failure, paroxysmal atrial fibrillation	+	+	–
P7 (DHF)	F	85	DENV-1	IFN-α2/IFN-ω	Survival	Abdominal pain, thrombocytopenia	59	91	29.8	++ Myocardial damage	–	–	–

No. and group	Sex	Age (years)	DENV serotype	NAbs	Outcomes	Symptoms	Hemorrhage-related parameters			Organ injury or abnormality
No. and group	Sex	Age (years)	DENV serotype	NAbs	Outcomes	Symptoms	PLT (×10⁹/L)	HB (g/L)	HCT (%)	Cardiac	Hepatic	Kidney	Lung
P1(DHF)	M	53	DENV-1	IFN-α2	Survival	Thrombocytopenia,mucosal bleeding	57	145	44.2	++Myocardial damage	++	–	–
P2(DHF)	F	78	DENV-1	IFN-α2	Survival	Hypoalbuminemia,palpitation	93	79	24	++Heart failure, myocarditis, and paroxysmal atrial fibrillation	–	+	–
P3(DHF)	M	86	DENV-1	IFN-α2	Survival	Diarrhea,mucosal bleeding	77	115	34.5	+Sinus bradycardia, aortic regurgitation, and left ventricular diastolic dysfunction	++	–	+
P4(DHF)	M	55	Unknown	IFN-ω	Survival	Abdominal discomfort, epistaxis, and thrombocytopenia	17	128	38.5	+Mitral regurgitation, and tricuspid regurgitation	++	–	–
P5(DSS)	F	48	DENV-1	IFN-ω	Death	Thrombocytopenia, abdominal pain, diarrhea,and septic shock	13	40	<15	++Myocarditis, paroxysmal atrial fibrillation	+	+	++
P6(DHF)	F	75	DENV-1	IFN-α2/IFN-ω	Survival	Thrombocytopenia,abdominal discomfort	14	123	38.2	++Heart failure, paroxysmal atrial fibrillation	+	+	–
P7(DHF)	F	85	DENV-1	IFN-α2/IFN-ω	Survival	Abdominal pain,thrombocytopenia	59	91	29.8	++Myocardial damage	–	–	–

P1–P3, the anti-IFN-α2 NAb group; P4 and P5, the anti-IFN-ω NAb group; and P6 and P7, the anti-IFN-α2 and anti-IFN-ω NAb group. F, female; M, male; PLT, platelet; HCT, hematocrit. +, organ dysfunction (hepatic/renal/pulmonary dysfunction, cardiac arrhythmia, etc.). ++, organ inflammation or injury (toxic hepatitis, myocarditis, myocardial injury, pneumonia, etc.).

[ViewLarge]

Sharing Unavailable